The Cooper Companies, Inc. $COO Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 11.1% during the second quarter, HoldingsChannel reports. The firm owned 383,736 shares of the medical device company’s stock after purchasing an additional 38,427 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Cooper Companies were worth $27,307,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. JPMorgan Chase & Co. increased its stake in Cooper Companies by 3.4% in the first quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company’s stock valued at $436,681,000 after purchasing an additional 172,485 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Cooper Companies by 17.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock valued at $399,340,000 after buying an additional 686,751 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Cooper Companies by 12.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,954,877 shares of the medical device company’s stock valued at $333,595,000 after acquiring an additional 425,400 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Cooper Companies by 36.0% during the 1st quarter. Millennium Management LLC now owns 2,577,416 shares of the medical device company’s stock worth $217,405,000 after acquiring an additional 682,166 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Cooper Companies by 15.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,121,835 shares of the medical device company’s stock worth $178,977,000 after acquiring an additional 284,943 shares during the period. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Insiders Place Their Bets

In other news, Director Lawrence Erik Kurzius purchased 2,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was acquired at an average cost of $68.39 per share, with a total value of $136,780.00. Following the acquisition, the director owned 5,777 shares in the company, valued at approximately $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Daniel G. Mcbride purchased 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were purchased at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the purchase, the chief operating officer directly owned 63,120 shares in the company, valued at $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 17,975 shares of company stock valued at $1,216,346. Corporate insiders own 1.98% of the company’s stock.

Cooper Companies Price Performance

COO stock opened at $71.74 on Wednesday. The firm has a market cap of $14.26 billion, a P/E ratio of 35.34, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $106.63. The stock has a 50-day simple moving average of $69.44 and a 200-day simple moving average of $72.44.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the company posted $0.96 EPS. Cooper Companies’s revenue for the quarter was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, equities analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a share repurchase plan on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages recently commented on COO. The Goldman Sachs Group set a $64.00 price target on shares of Cooper Companies and gave the stock a “sell” rating in a research report on Wednesday, October 1st. Barclays began coverage on Cooper Companies in a research report on Monday, October 13th. They issued an “overweight” rating and a $85.00 target price on the stock. JPMorgan Chase & Co. reduced their target price on Cooper Companies from $76.00 to $66.00 and set a “neutral” rating on the stock in a report on Thursday, August 28th. BNP Paribas Exane upgraded Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price target for the company in a research note on Tuesday, July 22nd. Finally, Weiss Ratings lowered Cooper Companies from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and an average price target of $84.77.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.